



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of : Confirmation No.

Akira MATSUMORI : Docket No. 2001_1881A

Serial No. 10/019,263 : Group Art Unit

Filed December 28, 2001 : Examiner

MEDICINAL COMPOSITIONS FOR PREVENTING OR TREATING VIRAL
MYOCARDITIS

1605
TELCENTER APR 2 2002
1000-2000
RECEIVED
U.S. PATENT AND TRADEMARK OFFICE

INFORMATION DISCLOSURE STATEMENT

Assistant Commissioner for Patents,
Washington, DC 20231

Sir:

Pursuant to the provisions of 37 CFR 1.56, 1.97 and 1.98, Applicants request consideration of [X] the references listed on attached form PTO-1449 and/or [] the additional information identified below in paragraph 3. A legible copy of each reference listed on the form PTO-1449 and each U.S. patent application listed below is enclosed, except a copy is not provided for each reference previously cited by or submitted to the Patent Office in prior parent application Serial No. .

1a. [X] This Information Disclosure Statement is submitted:

within three months of the filing date (or of entry into the National Stage) of the above-entitled application, or

before the mailing of a first Office Action on the merits or the mailing of a first Office Action after the filing of an RCE,

and thus no certification and/or fee is required.

1b. [] This Information Disclosure Statement is submitted

after the events of above paragraph 1a and prior to the mailing date of a final Office Action or a Notice of Allowance or an action which otherwise closes prosecution in the application, and thus:

- (1) the certification of paragraph 2 below is provided, or
- (2) the fee of \$180.00 specified in 37 CFR 1.17(p) is enclosed.

1c. This Information Disclosure Statement is submitted:

after the mailing date of a final Office Action or Notice of Allowance or action which otherwise closes prosecution in the application, and prior to payment of the issue fee, and thus:

the certification of paragraph 2 below is provided, and

the fee of \$180.00 specified in 37 CFR 1.17(p) is enclosed.

2. It is hereby certified

- a. that each item of information contained in this Information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the Statement, or
- b. that no item of information contained in the Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application and, to the knowledge of the person signing the certification after making reasonable inquiry, was known to any individual designated in §1.56(c) more than three months prior to the filing of the Statement.

3. Consideration of the following list of additional information (including any copending or abandoned U.S. application, prior uses and/or sales, etc.) is requested.

References AA and AB are the U.S. Patent equivalents of WO98/37875 and WO94/08943 cited in the International Search Report. The third reference cited in the International Search Report, WO98/03162, is an international publication of PCT/JP97/02448 (Applicant: Yoshitomi Pharmaceutical Industries, Ltd.). PCT/JP97/02448 was refiled as a CIP application in the US and this PCT application itself has not entered the national phase in the US or any other designated

state. The CIP application (Serial No. 09/231,484, filing date: January 14, 1999) has been refiled as CPA, which is now pending.

4. For each non-English language reference listed on the attached form PTO-1449, reference is made to:
 - a. a full or partial English language translation submitted herewith,
 - b. a foreign patent office search report (in the English language) submitted herewith,
 - c. the concise explanation contained in the specification of the present application at page 2,
 - d. the concise explanation set forth in the attached English language abstract,
 - e. the concise explanation set forth below or on a separate sheet attached to the reference:
5. A foreign patent office search report citing one or more of the references is enclosed.

Respectfully submitted,

Akira MATSUMORI

By Warren Cheek
Warren M. Cheek, Jr.
Registration No. 33,367
Attorney for Applicant

WMC/jmj
Washington, D.C. 20006-1021
Telephone (202) 721-8200
Facsimile (202) 721-8250
March 27, 2002